SAB Biotherapeutics, Inc.
NASDAQ Global MarketTotal Valuation
SAB Biotherapeutics, Inc. carries a market capitalization of 71,686.00, placing it among publicly traded companies globally. Its enterprise value stands at -96.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 71,686.00 |
| Enterprise Value | -96.43M |
Share Statistics
SAB Biotherapeutics, Inc. currently has 83.49M shares outstanding.
| Shares Outstanding | 83.49M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
SAB Biotherapeutics, Inc. maintains a current ratio of 9.22, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.39, indicating elevated leverage, while an interest coverage ratio of -296.79 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.22 |
| Quick Ratio | 8.93 |
| Debt / Equity | 2.39 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -296.79 |
Financial Efficiency
| Return on Equity (ROE) | -11.27 |
| Return on Assets (ROA) | -9.52 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 17.89 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
SAB Biotherapeutics, Inc.'s stock has declined approximately -74.66216% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -74.66216% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -68.71M, while operating income came in at -71.82M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -71.82M |
| Pretax Income | -12.78M |
| Net Income | -12.78M |
| EBITDA | -68.71M |
| EBIT | -71.82M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
SAB Biotherapeutics, Inc. holds 102.63M in cash and equivalents against 5.13M in total debt, resulting in a net debt position of -8.27M. Total book value stands at 214.79M, with working capital of 96.23M providing operational flexibility.
| Cash & Cash Equivalents | 102.63M |
| Total Debt | 5.13M |
| Net Debt | -8.27M |
| Equity (Book Value) | 214.79M |
| Book Value Per Share | 2.57 |
| Working Capital | 96.23M |
Cash Flow
SAB Biotherapeutics, Inc. produced -53.94M in operating cash flow over the past twelve months.
| Operating Cash Flow | -53.94M |
| Capital Expenditures | -3.50M |
| Free Cash Flow | -57.44M |
| FCF Per Share | N/A |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -24,415.62 |
| FCF Yield | N/A |
Scores
SAB Biotherapeutics, Inc. posts an Altman Z-Score of -1.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.38 |